Opinion|Videos|February 15, 2024
Platforms for Testing MRD in CRC
Arvind N. Dasari, MD, MS, provides clinical insights on MRD testing modalities, highlighting factors that inform the decision on which platform to use in practice.
Advertisement
Episodes in this series
Advertisement
Related to this article
More than half of patients with microsatellite-stable metastatic colorectal cancer without active liver metastases survived at least 18 months with botensilimab plus balstilimab.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumors
2
FDA Approves OncoMate MSI Dx as Pembrolizumab Companion Diagnostic in MSI-H Solid Tumors
3
Hyperthermic Mitomycin C Yields 68% 1-Year HG-RFS in BCG-Unresponsive NMIBC
4
FDA Accepts sNDA for Gedatolisib in PIK3CA-Mutant HR+/HER2– Breast Cancer
5